IFRX:NSD-InflaRx N.V. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.51

Change

+0.01 (+0.40)%

Market Cap

USD 0.14B

Volume

0.05M

Analyst Target

USD 9.28
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.91 (+0.72%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

-0.66 (-0.09%)

USD 84.94B
ARGX argenx NV ADR

+1.67 (+0.27%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+0.99 (+0.41%)

USD 31.66B
BGNE BeiGene Ltd

+3.92 (+2.21%)

USD 20.24B
UTHR United Therapeutics Corporatio..

-2.78 (-0.76%)

USD 16.18B
MRNA Moderna Inc

+0.68 (+1.72%)

USD 16.10B
RPRX Royalty Pharma Plc

-0.02 (-0.08%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.33 (+1.77%)

USD 13.67B
INCY Incyte Corporation

+0.07 (+0.10%)

USD 13.52B

ETFs Containing IFRX

XEG:CA iShares S&P/TSX Capped En.. 5.38 % 0.61 %

+0.13 (+0.63%)

CAD 1.64B
WXM:CA First Asset Morningstar C.. 3.33 % 0.67 %

+0.19 (+0.63%)

CAD 0.58B
XMD:CA iShares S&P/TSX Completio.. 2.19 % 0.61 %

+0.16 (+0.63%)

CAD 0.23B
VSS Vanguard FTSE All-World e.. 0.34 % 0.12 %

+0.43 (+0.63%)

USD 8.36B
ENY 0.00 % 0.66 %

N/A

N/A
FQC:CA 0.00 % 1.01 %

N/A

N/A
HEE:CA 0.00 % 0.84 %

N/A

N/A
SCHC Schwab International Smal.. 0.00 % 0.12 %

+0.17 (+0.63%)

N/A
ZJO:CA 0.00 % 0.60 %

N/A

N/A
BREA:CA Brompton Sustainable Real.. 0.00 % 0.00 %

+0.17 (+0.63%)

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 53.99% 84% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.99% 84% B 87% B+
Trailing 12 Months  
Capital Gain 48.52% 82% B 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.52% 82% B 86% B+
Trailing 5 Years  
Capital Gain -44.71% 62% D 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.71% 62% D 27% F
Average Annual (5 Year Horizon)  
Capital Gain -5.82% 39% F 26% F
Dividend Return -5.82% 39% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 73.27% 48% F 28% F
Risk Adjusted Return -7.94% 39% F 29% F
Market Capitalization 0.14B 51% F 42% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.